B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2020

February 2020 | 211 pages | ID: B548A0B2E07EN
Global Markets Direct

Abstracts

B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2020, provides an overview of the B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline landscape.

B-Cell Chronic Lymphocytic Leukemia is a type of slow growing leukemia that affects developing B-lymphocytes (also known as B-cells). Symptoms include swollen lymph nodes (glands) in the neck, under the arms or in the groin, pain or discomfort under the ribs on the left side, due to an enlarged spleen, frequent or repeated infections and slow healing, due to a lack of normal white blood cells, excessive sweating at night and unintentional weight loss. Treatment includes chemotherapy and radiation.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for B-Cell Chronic Lymphocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for B-Cell Chronic Lymphocytic Leukemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 10, 11, 1 and 8 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed and Preclinical stages comprises 2, 1, 1 and 1 molecules, respectively.

B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of B-Cell Chronic Lymphocytic Leukemia (Oncology).
• The pipeline guide reviews pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in B-Cell Chronic Lymphocytic Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates B-Cell Chronic Lymphocytic Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia (Oncology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for B-Cell Chronic Lymphocytic Leukemia (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
B-Cell Chronic Lymphocytic Leukemia - Overview
B-Cell Chronic Lymphocytic Leukemia - Therapeutics Development
B-Cell Chronic Lymphocytic Leukemia - Therapeutics Assessment
B-Cell Chronic Lymphocytic Leukemia - Companies Involved in Therapeutics Development
B-Cell Chronic Lymphocytic Leukemia - Drug Profiles
B-Cell Chronic Lymphocytic Leukemia - Dormant Projects
B-Cell Chronic Lymphocytic Leukemia - Discontinued Products
B-Cell Chronic Lymphocytic Leukemia - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
B-Cell Chronic Lymphocytic Leukemia - Pipeline by AB Science SA, H1 2020
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Aduro BioTech Inc, H1 2020
B-Cell Chronic Lymphocytic Leukemia - Pipeline by AstraZeneca Plc, H1 2020
B-Cell Chronic Lymphocytic Leukemia - Pipeline by BeiGene Ltd, H1 2020
B-Cell Chronic Lymphocytic Leukemia - Pipeline by BioIntegrator Ltd, H1 2020
B-Cell Chronic Lymphocytic Leukemia - Dormant Projects, H1 2020
B-Cell Chronic Lymphocytic Leukemia - Dormant Projects, H1 2020 (Contd..1), H1 2020
B-Cell Chronic Lymphocytic Leukemia - Dormant Projects, H1 2020 (Contd..2), H1 2020
B-Cell Chronic Lymphocytic Leukemia - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

AB Science SA
Aduro BioTech Inc
AstraZeneca Plc
BeiGene Ltd
BioIntegrator Ltd
BioInvent International AB
BioXpress Therapeutics SA
Bristol-Myers Squibb Co
CRISPR Therapeutics AG
Elsalys Biotech SA
Generon (Shanghai) Corp Ltd
iDD biotech SAS
Juno Therapeutics Inc
Loxo Oncology Inc
Merck & Co Inc
Millennium Pharmaceuticals Inc
Molecular Templates Inc
Nordic Nanovector ASA
Novartis AG
Noxxon Pharma AG
Oncology Venture U.S. Inc
Ono Pharmaceutical Co Ltd
Portola Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
Samumed LLC
Shanghai Pharmaceutical Group Co Ltd
Sunesis Pharmaceuticals Inc
TheraMAB LLC
Xencor Inc
Zhejiang DTRM Biopharma LLC